# STAMPEDE (NCT00268476)

> Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

No report yet. It can be ordered.

- Drugs tested: abiraterone; docetaxel; abiraterone plus enzalutamide
- Indication: locally advanced or metastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00268476
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Medical Research Council
- Conditions: Prostate Cancer
- Interventions: Celecoxib; Docetaxel; Prednisolone; ADT; Zoledronic Acid; Abiraterone; Radiotherapy to the prostate; Enzalutamide; Metformin; Transdermal Oestradiol
- Enrollment: 11992
- Primary outcome: Overall survival

## Indexed commentary on STAMPEDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=stampede-nct00268476